Pfizer and Merck terminated Bavencio's Phase III study

Pfizer and Merck have announced that they will terminate Bavencio's Phase III JAVELIN Ovarian 100 study because the data does not support the preliminary assumptions of the study.An interim analysis of theprogram showed that the drug had no advantage in predetermined non-progressive lifetime (PFS), where the main endpoint was PFS, which benefited one or both of Bavencio's options rather than just chemotherapy.The study involved 988 previously untreated patients with localized advanced or metastatic epitheliotic ovary, fallopian tubes, or primary peritometrial cancer. JAVELIN Ovarian PARP 100 studies and early stage studies are still under way to study drugs in a variety of combinations.A spokesman for the two companies said: "Although detailed analysis of the data is under way, no new safety signals have been observed and the safety characteristics of anti-PD-L1 antibodies in the trial appear to be consistent with across JAVELIN clinical development." Theythe details of the study would be shared with the scientific community.Every year, more than 295,000 women worldwide are diagnosed with ovarian cancer, and unfortunately, the process of diagnosing ovarian cancer tends to be advanced because it is often difficult to detect at an early stage with almost no symptoms.The five-year survival rate is about 30 to 50 per cent, but for those with metastasis diseases, which have spread to other parts of the body, the five-year survival rate drops to less than 20 per cent. (Compiled by this web)